Literature DB >> 21178272

Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome.

Qian Zhang1, Jeremiah C Davis, Christopher G Dove, Helen C Su.   

Abstract

DOCK8 immunodeficiency syndrome (DIDS) is a combined immunodeficiency characterized by recurrent viral infections, severe atopy, and early onset malignancy. Genetic studies revealed large, unique deletions in patients from different families and ethnic backgrounds. Clinical markers of DIDS include atopic dermatitis, allergies, cutaneous viral infections, recurrent respiratory tract infections, and malignancy. Immune assessments showed T cell lymphopenia, hyper-IgE, hypo-IgM, and eosinophilia. The impaired lymphocyte functions in DIDS patients appear central for disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178272      PMCID: PMC3835385          DOI: 10.3233/DMA-2010-0737

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  34 in total

1.  Cutaneous manifestations of DOCK8 deficiency syndrome.

Authors:  Emily Y Chu; Alexandra F Freeman; Huie Jing; Edward W Cowen; Joie Davis; Helen C Su; Steven M Holland; Maria L Chanco Turner
Journal:  Arch Dermatol       Date:  2011-09-19

2.  Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait.

Authors:  Waleed Al-Herz; Raj Ragupathy; Michel J Massaad; Raja'a Al-Attiyah; Arti Nanda; Karin R Engelhardt; Bodo Grimbacher; Luigi Notarangelo; Talal Chatila; Raif S Geha
Journal:  Clin Immunol       Date:  2012-03-30       Impact factor: 3.969

3.  The clinical and laboratory spectrum of dedicator of cytokinesis 8 immunodeficiency syndrome in patients with a unique mutation.

Authors:  Arnon Broides; Amarilla B Mandola; Jacov Levy; Baruch Yerushalmi; Vered Pinsk; Michal Eldan; George Shubinsky; Nurit Hadad; Rachel Levy; Amit Nahum; Miriam Ben-Harosh; Atar Lev; Amos Simon; Raz Somech
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

4.  Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis.

Authors:  H Zhao; W Cai; S Su; D Zhi; J Lu; S Liu
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

Review 5.  DOCK8 deficiency: Insights into pathophysiology, clinical features and management.

Authors:  Catherine M Biggs; Sevgi Keles; Talal A Chatila
Journal:  Clin Immunol       Date:  2017-06-15       Impact factor: 3.969

Review 6.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

7.  Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency.

Authors:  Angela Sabry; Pia J Hauk; Huie Jing; Helen C Su; Nicholas V Stence; David M Mirsky; Maria A Nagel; Jordan K Abbott; Leonard L Dragone; Jennifer Armstrong-Wells; Donna J Curtis; Randall Cohrs; D Scott Schmid; Don Gilden; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2014-01-11       Impact factor: 10.793

Review 8.  Current Status of Dedicator of Cytokinesis-Associated Immunodeficiency: DOCK8 and DOCK2.

Authors:  Dimana Dimitrova; Alexandra F Freeman
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 9.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

10.  Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients.

Authors:  Zobaida Alsum; Abbas Hawwari; Osama Alsmadi; Safa Al-Hissi; Esteban Borrero; Asma' Abu-Staiteh; Hanif G Khalak; Salma Wakil; Abdelmoneim M Eldali; Rand Arnaout; Abdulaziz Al-Ghonaium; Saleh Al-Muhsen; Hasan Al-Dhekri; Bandar Al-Saud; Hamoud Al-Mousa
Journal:  J Clin Immunol       Date:  2012-09-12       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.